Bispecific Antibodies and Antibody Drug Conjugates: More Complex and Targeted Biologic Therapeutics

Bispecific Antibodies and Antibody Drug Conjugates: More Complex and Targeted Biologic Therapeutics

With the maturation of monoclonal antibodies (mAbs) based cancer immunotherapy drugs that target specific, actionable biomarkers, the biopharmaceutical industry has been developing more complex mAbs, such as bispecific antibodies and antibody drug conjugates. The Business Research Company projects the global monoclonal antibody market will exceed USD 170 billion by 2025 at a 12.9 percent CAGR. And in Asia, several companies are leading the way with these advanced antibody drug pipelines, including Astellas and Daiichi Sankyo in Japan, Adpro in Korea, and Miracogen in China.